AU2006320264A1 - Composition and use of phyto-percolate for treatment of disease - Google Patents

Composition and use of phyto-percolate for treatment of disease Download PDF

Info

Publication number
AU2006320264A1
AU2006320264A1 AU2006320264A AU2006320264A AU2006320264A1 AU 2006320264 A1 AU2006320264 A1 AU 2006320264A1 AU 2006320264 A AU2006320264 A AU 2006320264A AU 2006320264 A AU2006320264 A AU 2006320264A AU 2006320264 A1 AU2006320264 A1 AU 2006320264A1
Authority
AU
Australia
Prior art keywords
percolate
phyto
derivative
compound
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006320264A
Other languages
English (en)
Inventor
Tiffany Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zivo Bioscience Inc
Original Assignee
Health Enhancement Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Enhancement Products Inc filed Critical Health Enhancement Products Inc
Publication of AU2006320264A1 publication Critical patent/AU2006320264A1/en
Priority to AU2013204257A priority Critical patent/AU2013204257A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • AIDS & HIV (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2006320264A 2005-04-20 2006-12-04 Composition and use of phyto-percolate for treatment of disease Abandoned AU2006320264A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204257A AU2013204257A1 (en) 2005-04-20 2013-04-12 Composition and use of phyto-percolate for treatment of disease

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPCT/US2005/013375 2005-04-20
US60/719,025 2005-09-21
US74177405P 2005-12-02 2005-12-02
US60/741,774 2005-12-02
PCT/US2006/046320 WO2007065024A2 (en) 2005-12-02 2006-12-04 Composition and use of phyto-percolate for treatment of disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/015302 Division WO2006113925A2 (en) 2004-04-23 2006-04-20 Composition and use of phyto-percolate for treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013204257A Division AU2013204257A1 (en) 2005-04-20 2013-04-12 Composition and use of phyto-percolate for treatment of disease

Publications (1)

Publication Number Publication Date
AU2006320264A1 true AU2006320264A1 (en) 2007-06-07

Family

ID=38092904

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006320264A Abandoned AU2006320264A1 (en) 2005-04-20 2006-12-04 Composition and use of phyto-percolate for treatment of disease

Country Status (5)

Country Link
EP (1) EP1954800A4 (enExample)
JP (1) JP2009518312A (enExample)
AU (1) AU2006320264A1 (enExample)
CA (1) CA2631773C (enExample)
WO (1) WO2007065024A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110117122A1 (en) * 2009-11-16 2011-05-19 Tiffany Thomas COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-kB
US7807622B2 (en) 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
CA2625818A1 (en) 2005-04-20 2006-10-26 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
CA2827401A1 (en) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents and mechanisms for treating hypercholesterolemia
US20160051526A1 (en) * 2013-04-09 2016-02-25 Cresset Biomolecular Discovery Ltd The Local Treatment of Inflammatory Ophthalmic Disorders
WO2014201372A1 (en) 2013-06-13 2014-12-18 Health Enhancement Products, Inc. Compounds and methods for affecting cytokines
ES2972377T3 (es) 2015-02-16 2024-06-12 Zivo Bioscience Inc Composiciones antinflamatorias e inmunomoduladoras que comprenden Klebsormidium y usos de las mismas
US11806375B2 (en) 2016-02-16 2023-11-07 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1307213B1 (en) * 2000-08-10 2004-04-28 Ocean Nutrition Canada Ltd. Chlorella preparations exhibiting immunomodulating properties
WO2005112987A2 (en) * 2004-04-23 2005-12-01 Health Enhancement Products, Inc. Method of preparation and use of fibrinolytic enzymes in the treatment of disease

Also Published As

Publication number Publication date
JP2009518312A (ja) 2009-05-07
EP1954800A2 (en) 2008-08-13
WO2007065024A2 (en) 2007-06-07
EP1954800A4 (en) 2010-03-03
CA2631773C (en) 2022-04-26
WO2007065024A3 (en) 2008-01-10
CA2631773A1 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
US8791060B2 (en) Composition and use of phyto-percolate for treatment of disease
de Alencar Alves et al. Antihyperglycemic and antioxidant activities of a lectin from the marine red algae, Bryothamnion seaforthii, in rats with streptozotocin-induced diabetes
CN102671009A (zh) 植物发酵提取物及其粉末以及其组合物的制造方法
US20130251698A1 (en) Composition and method for affecting cytokines and nf-kb
CA2631773C (en) Composition and use of phyto-percolate for treatment of disease
US10166270B2 (en) Composition and method for affecting cytokines and NF-κB
US20080031863A1 (en) Method of Preparation and Use of Fibrinolytic Enzymes in the Treatment of Disease
US8586053B2 (en) Composition and use of phyto-percolate for treatment of disease
WO2006113925A2 (en) Composition and use of phyto-percolate for treatment of disease
Tu et al. Protective role of bayberry extract: associations with gut microbiota modulation and key metabolites
CA2776919C (en) Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing
CN114699424A (zh) 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用
RU2426552C2 (ru) Экстракты phaseolus vulgaris, их применение и композиции, содержащие их
Jia et al. The potential auxiliary effects of Sargassum fusiform polysaccharides on sitagliptin in the treatment of diabetes mellitus
AU2013204257A1 (en) Composition and use of phyto-percolate for treatment of disease
JP2004099613A (ja) 自己免疫疾患治療用ガノデルマルシダム胞子
TW201619390A (zh) 一種製備具有抗凝血活性的海藻寡糖的方法
Al-Jowari Comparative investigation of amoxicillin and cephalexin administration on some biochemical parameters in male rabbits
Wu et al. Acanthopanax trifoliatus (L.) Merr polysaccharides: A novel therapeutic agent for hyperuricemia management
WO2020260358A1 (fr) Bacteries du microbiote intestinal et composition en contenant pour son utilisation dans la prevention et/ou le traitement de maladies caracterisees par l'exces de 2-hydroxyglutarate
RU2432957C2 (ru) Способ получения средства, обладающего гастрозащитной активностью
Schneider The Tubercular Constitution as a Common Cause of Chronic Diseases and its Treatment with Naturopathic “Regulation Therapy “
RU2673555C2 (ru) Способ применения "Ягель детокс" в качестве средства для лечения туберкулеза с множественной лекарственной устойчивостью
CN121754566A (zh) 一种功能性黑木耳多糖-牛奶复配物及其制备方法与应用
CN120241721A (zh) 麦角硫因在制备肾损伤保护药物的应用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE DIVISIONAL TO READ 2006236161

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
TH Corrigenda

Free format text: IN VOL 27 , NO 16 , PAGE(S) 2174 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN, PATENTS CEASED OR EXPIRED - 2006 DELETE ALL REFERENCE TO 2006320264.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted